前蛋白转化酶枯草溶菌素9抑制剂与心血管事件 - Suppr

PCSK9 Inhibitors and Cardiovascular Events.

作者信息

Robinson Jennifer G, Kastelein John J P

出版信息

N Engl J Med. 2015 Aug 20;373(8):774. doi: 10.1056/NEJMc1508222.

DOI:10.1056/NEJMc1508222

PMID:26287854

Abstract

摘要

相似文献

PCSK9 Inhibitors and Cardiovascular Events.

N Engl J Med. 2015 Aug 20;373(8):774. doi: 10.1056/NEJMc1508222.

PCSK9 Inhibitors and Cardiovascular Events.

N Engl J Med. 2015 Aug 20;373(8):773. doi: 10.1056/NEJMc1508222.

PCSK9 Inhibitors and Cardiovascular Events.

N Engl J Med. 2015 Aug 20;373(8):774-5. doi: 10.1056/NEJMc1508222.

PCSK9 Inhibitors and Cardiovascular Events.

N Engl J Med. 2015 Aug 20;373(8):773-4. doi: 10.1056/NEJMc1508222.

PCSK9 inhibitors reduce cardiovascular events, preliminary data show.

BMJ. 2015 Mar 17;350:h1508. doi: 10.1136/bmj.h1508.

Lowering LDL cholesterol is good, but how and in whom?

N Engl J Med. 2015 Apr 16;372(16):1564-5. doi: 10.1056/NEJMe1502192. Epub 2015 Mar 15.

Dyslipidaemia. Assessing the efficacy and safety of evolocumab and alirocumab.

Nat Rev Cardiol. 2015 May;12(5):261. doi: 10.1038/nrcardio.2015.51. Epub 2015 Mar 31.

PCSK9 inhibition: the next statin?

J Am Coll Cardiol. 2012 Jun 19;59(25):2354-5. doi: 10.1016/j.jacc.2012.03.011. Epub 2012 Mar 31.

Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial.

JAMA. 2017 Aug 22;318(8):748-750. doi: 10.1001/jama.2017.9924.

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

N Engl J Med. 2015 Apr 16;372(16):1489-99. doi: 10.1056/NEJMoa1501031. Epub 2015 Mar 15.

引用本文的文献

Circulating Hematopoietic Stem/Progenitor Cells are Associated with Coronary Stenoses in Patients with Coronary Heart Disease.

Sci Rep. 2019 Feb 8;9(1):1680. doi: 10.1038/s41598-018-38298-5.

Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.

Vasc Health Risk Manag. 2017 Jul 6;13:247-253. doi: 10.2147/VHRM.S133690. eCollection 2017.

Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study.

Lipids Health Dis. 2017 Jul 24;16(1):141. doi: 10.1186/s12944-017-0493-7.

PCSK9 and Atherosclerosis - Lipids and Beyond.

J Atheroscler Thromb. 2017 May 1;24(5):462-472. doi: 10.5551/jat.RV17003. Epub 2017 Mar 9.

Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study.

Lipids Health Dis. 2017 Jan 23;16(1):19. doi: 10.1186/s12944-017-0416-7.

Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center.

Lipids Health Dis. 2016 Aug 18;15(1):132. doi: 10.1186/s12944-016-0302-8.

Association of Exome Sequences With Cardiovascular Traits Among Blacks in the Jackson Heart Study.

Circ Cardiovasc Genet. 2016 Aug;9(4):368-74. doi: 10.1161/CIRCGENETICS.116.001410. Epub 2016 Jul 15.

A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab.

J Manag Care Spec Pharm. 2016 Jun;22(6):641-653q. doi: 10.18553/jmcp.2016.22.6.641.

Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapy.

Lipids Health Dis. 2016 Mar 12;15:55. doi: 10.1186/s12944-016-0227-2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

PCSK9 Inhibitors and Cardiovascular Events.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

PCSK9 Inhibitors and Cardiovascular Events.

作者信息

出版信息

相似文献

引用本文的文献